Name
Title
Email
Robert Goldsmith
Senior Vice President, Sales, MJH Life Sciences & OncLive®
rgoldsmith@mjhassoc.com
Lisa Greene
Vice President, Sales, OncLive® Medical
lgreene@onclive.com
Albert Tierney
Senior Director, Sales, OncLive®
atierney@onclive.com
Morgan Michon
Director of Sales, OncLive®
mmichon@onclive.com
Shane Marchesani
National Accounts Manager, OncLive®
smarchesani@onclive.com
Elisha Garcia
Senior Accounts Manager, OncLive® Events
egarcia@onclive.com
Chelsea DeLisa
National Accounts Manager, OncLive® Events
cdelisa@onclive.com
Gabby Gelchion
National Accounts Associate, OncLive® Events
ggelchion@onclive.com
Alyssa Tomaseck
Business Development Associate, OncLive® Medical
atomaseck@onclive.com
Mike DiGrazia
Inside Sales Associate, OncLive®
mdigrazia@onclive.com
Noelle Stango
Strategic Alliance Partnership Coordinator, OncLive® & ONN
nstango@mjhlifesciences.com
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer